Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Antibiotics - They’re amazing, but they don’t work on viral infections like the cold and flu

YourUpdateTV

As consumers struggle to navigate yet another heavy-hitting cold and flu season, it is important to uncover the misconceptions surrounding the alarming overuse of antibiotics, especially the misuse in treating viral infections like the common cold and flu. Recently, Dr. Ken Redcross, conducted a satellite media tour to share tips and advice on how to safely and effectively manage cold or flu symptoms. A video accompanying this announcement is available at: https://youtu.be/0aIOL11vnss Every year, approximately 2.8 million antibiotic-resistant infections occur and 35,000 people in the US die from Antimicrobial Resistance (AMR), a global health emergency caused by common misconceptions about the effectiveness of antibiotics in treating cold and flu symptoms, which over time can lead to rampant antibiotic overuse and antibiotic resistance. To raise awareness of this global health crisis and help fight these misconceptions, Mucinex – a brand made by Reckitt which clears the way for people to make powerful comebacks from sickness with its line of over-the-counter cold and flu medications – is launching its new “Flip the Script” campaign. This multi-pronged initiative aims to educate consumers about the widespread inappropriate use of antibiotics currently plaguing the U.S. and the world at large. The brand will partner with Urgent and Primary Care Centers to help address this issue. There’s a reason for that: 7 in 10 Urgent Care Center patients ask their doctor for an antibiotic and 45.7% of inappropriate antibiotic prescriptions for Respiratory diagnoses were from Urgent Care centers. That’s why Mucinex plans to roll out signage and educational materials at Urgent and Primary Care Centers, as well as a series of educational videos and audio PSAs online, which clearly explain why OTC products like Mucinex – not antibiotics – are still the best option for treating cold and flu symptoms. Antibiotic Resistance caused partly by this misuse of antibiotics is a leading cause of death worldwide. This misuse stems largely from two common and incorrect misconceptions: that antibiotics are the best line of defense against cold and flu symptoms and that antibiotics are essential when cold and flu symptoms last longer than two or three days. Mucinex’s partnership with Urgent and Primary Care Centers throughout the nation will focus on states that have a high index of certain AMR strains and antibiotic prescriptions per population. How can consumers Flip the Script? Those who visit participating urgent care centers will find educational materials about antibiotic resistance, urging them to reach out to their physician when feeling unwell so that the proper treatment can be prescribed. Should the physician recommend an over-the-counter medication, they can share a “prescription” with the patient—an informative flipped brochure about antibiotics vs. OTC medication — that includes a Mucinex coupon, making it simpler to relieve your worst cold and flu symptoms at any time, day or night. For more information on the campaign and real-life examples of people struggling with the effects of AMR, visit the “Flip the Script” landing page on the Mucinex website at Mucinexfight.com. For more information on Mucinex, visit www.Mucinex.com. ABOUT: Dr. Ken Redcross, M.D. Dr. Redcross is a board-certified Internal Medicine physician. His expertise is capturing how to best provide the ultimate patient experience for those frustrated with the deterioration of the patient-doctor relationship. His concierge approach has led to the development of an impressive following of patients from the entertainment industry, sports world and business leaders spanning from Los Angeles to New York City. Dr. Redcross has reached tens of millions of people through media appearances including The Doctors, Entertainment Tonight and the Nancy Grace Show. He has been a medical expert for CNN Travel appeared regularly on HLN Weekend Express and has contributed articles for and digital health and wellness companies, including Everyday Health. Dr. Redcross has worked with a diverse group of patients, spanning from the elderly to migrant farm workers, to patients battling heroin addiction. He participated in fellowships in Puerto Rico and the Dominican Republic, contributing to his proficiency in Spanish. In 2001, Dr. Redcross completed his medical training at the prestigious Columbia-Presbyterian Medical Center, followed by providing care in rural Oxnard, CA and finally transitioning to the renowned Cedars-Sinai Medical Center in Beverly Hills. Following his year of accumulated training and experience, he created his Concierge practice in 2007, and established his wellness company, Ken Redcross Communications, Inc. As an author, Dr. Redcross shares his nearly 20 years of experience in his book, Bond: The 4 Cornerstones of a Lasting and Caring Relationship with Your Doctor, where he highlights the four cornerstone qualities essential to creating a life-long patient-doctor bond. Bond was the Amazon Number One New Release in Medicine & Psychology. Among his many honors, Dr. Redcross received the Man of Valor Award from NAACP Youth Council for excellence in medicine and most recently, was named a Top 25 Concierge Physician in the U.S. Embracing both natural and alternative methods of healing in his practice, Dr. Redcross received the honor of being selected Educator of the Year by the Nutrition Business Journal (NBJ). He firmly believes that proactive treatment is the goal, and if medical challenges arise, they should be met with support through the creation of a health strategy. With the correct balance of nutrition, movement, and spirituality we can live our best life experience. Currently, Dr. Redcross focuses on utilizing the BOND program to consult for health networks and companies to provide their customers with better outcomes while serving as an advocate, educating, empowering, and offering peace of mind to patients and their families. About Reckitt Reckitt* exists to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. We believe that access to the highest-quality hygiene, wellness and nourishment is a right, not a privilege. Reckitt is the company behind some of the world's most recognizable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and more. Every day, more than 30 million Reckitt products are bought globally. We always put consumers and people first, seek out new opportunities, strive for excellence in all that we do and build shared success with all our partners. We aim to do the right thing, always. We are a diverse global team of c. 40,000 colleagues. We draw on our collective energy to meet our ambitions of purpose-led brands, a healthier planet and a fairer society. Find out more, or get in touch with us at www.reckitt.com/us. * Reckitt is the trading name of the Reckitt Benckiser group of companies [1] The Lancet Journal – Global Burden of Bacterial Antibiotic Resistance in 2019 [2] CDC 2019 Antibiotic Resistance Threats Report [3] 2022 Mucinex Urgent Care Patient Study [4] 2018 JAMA report - Overprescription in Urgent Care Clinics Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

December 26, 2023 10:39 AM Eastern Standard Time

Video

Neural Therapeutics CEO defines success and senses "a lot of momentum" behind psychedelics

Neural Therapeutics Inc.

Neural Therapeutics Inc CEO Ian Campbell speaks to Thomas Warner from Proactive about his vision for revolutionising mental health treatment. The company is working to develop medicines from from the San Pedro plant, in a challenge to traditional pharmaceutical methods that typically isolate single compounds. Campbell, with a diverse background in physical sciences, biology, toxicology, and engineering, explains that he transitioned to this field driven by a desire to contribute positively to humanity. His journey reflects a commitment to lifelong education and a passion for impactful scientific innovation. The CEO's personal connection to mental health issues within his family further motivates his mission, receiving supportive feedback from his family on this career shift. Currently, the company is focused on advancing their treatment into human clinical trials, navigating regulatory challenges and exploring the potential of botanicals in pharmaceuticals. Campbell's goal is to fast-track the drug's development, backed by evidence of mescaline's efficacy in treating various mental ailments. He says success for him would be "our product being delivered to humans." Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

December 21, 2023 08:20 AM Eastern Standard Time

Video

News Release

ReShape Lifesciences announces FDA PMA supplement approval for next-gen Lap-Band 2.0 Flex

ReShape Lifesciences Inc

ReShape Lifesciences CEO Paul Hickey joined Steve Darling from Proactive to share significant news regarding the approval of the company's next-generation Lap-Band® 2.0 FLEX by the U.S. Food and Drug Administration. Hickey told Proactive this FDA approval represents a historic event for ReShape Lifesciences and is expected to serve as a pivotal driver of growth for the company's Lap-Band franchise. The development of the enhanced Lap-Band 2.0 FLEX was led by physicians with a primary focus on improving the overall patient experience. This FDA approval marks a significant milestone for ReShape Lifesciences, highlighting the company's commitment to advancing patient-centered innovations in the field of medical devices. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

December 21, 2023 07:00 AM Eastern Standard Time

Video

Polarean Imaging "very excited" to announce brand new customer for XENOVIEW polariser

Polarean Imaging PLC

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) CEO Christopher von Jako speaks to Thomas Warner from Proactive after the medical imaging technology company announced its first de novo order for its XENOVIEW polariser. Von Jako explains that the latest order, from a renowned medical institution in the Northeast, represents a significant step as it is from a brand new customer. Von Jako, who took the helm in July, also highlights the company's work with Dutch multinational Philips, emphasising the seamless integration of their products, including FDA-approved MRI coils. This collaboration extends to training Philips' commercial staff in the U.S., promising further growth in 2024. Additionally, Polarean is pursuing strategic growth initiatives, including increasing utilisation of their technology at sites like Cincinnati Children's Hospital and the University of Missouri. The company is also focusing on expanding its footprint and establishing Medicare reimbursement, thus enhancing its financial viability. Another key initiative involves conducting a clinical trial for FDA approval to explore new lung functions, potentially revolutionising lung imaging technology. In terms of financials, von Jako expressed confidence in closing the funding gap by the third quarter of the next year, supported by strategic investors. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 21, 2023 06:55 AM Eastern Standard Time

Video

New Study From San Antonio Breast Cancer Symposium Proves Innovative Marker Makes It Easier for Physicians to Detect and Remove Cancer Than Ever Before

Endomag

Research presented at the San Antonio Breast Cancer Symposium (SABCS) has found that surgeons and radiologists are moving away from one of the oldest traditional methods for locating and removing breast cancer, in favour of newer and more innovative technologies. The seminal study found that since 2020, usage rates of the guidewire – the standard in breast cancer surgery for over 60 years - has fallen from 83% of physicians using the device, to just 18%. In comparison, the rise of a unique metallic seed called the Magseed® marker has seen its adoption levels soar to 49%, meaning it has replaced the guidewire as the most used method for cancer localization. Having gained FDA approval in 2015, the Magseed has helped over 250,000 patients worldwide to access minimally-invasive, wire-free breast cancer care. Gone are the days of a patient attending an early appointment to have a guidewire placed on the day of their surgery, and having to wait around the hospital until the time of operation. Now, patients have the option of the Magseed being placed into the cancerous tissue any time ahead of surgery, at a time that suits them, safe in the knowledge it won’t move and can be easily found when the surgery takes place at a later date. “This study demonstrates that the modern solutions to localization are providing such a vast improvement for patients and the physicians using them, that they have been able to be rapidly adopted across the hospital setting.” said Mr. James Harvey, Oncoplastic Breast Surgeon and author of the study presented at SABCS 2023. The study from SABCS also surveyed each of the participating surgeons and radiologists, to understand the quality of user experience for each of their chosen devices for localizing tumors. Participants were asked about a range of topics including the reliability of locating the device, accuracy of cancer removal and the logistical benefits that the technology provides to the hospital. Once again, the results showed a significant benefit in favour of the wire-free Magseed device. On average, radiologists gave the device 9/10 for overall satisfaction, while surgeons scored it 8/10. In comparison, the guidewire received 7/10 scores from both audiences. “This is the first study to demonstrate that radiologists and surgeons now find Magseed to be more effective in patient care and a significant improvement on prior technologies.” continued Mr. Harvey. It is also the first study to ascertain the advantages and disadvantages of each localization device against one another. The findings here could now have far-reaching implications for breast cancer treatment across the world. The shift towards Magseed as the preferred localization device indicates there is growing interest in new technologies that improve patient outcomes. The landscape is changing for breast surgery, and it’s helping to drive ongoing research and innovation in cancer care. -ENDS- Notes to Editors: In the study, participants were asked to rate a range of features on a scale from 1-10 (10 being the highest level of satisfaction). Please find poster attached alongside this press release. This iBRA-NET satisfaction study includes findings from 84 breast units (65% of all UK sites), and was published at the San Antonio Breast Cancer Symposium on 7th December 2023. The Sentimag platform, along with Magseed marker and Magtrace lymphatic tracer, was developed by Endomag and is distributed by Mammotome in North America. More than 450,000 women have now received a better standard of breast cancer surgery with Endomag’s technologies. The Sentimag® is in use at over 1,000 hospitals in more than 45 countries across the world. About Us At Endomag, we believe everyone deserves a better standard of cancer care. That’s why we design our magnetic technologies with both the clinician and patient in mind. Many leading hospitals across the world use our unique solutions to help breast cancer patients avoid surgery when it isn’t needed, and experience better outcomes when it is. At the heart of the company’s technologies is the Sentimag® localization system. The Sentimag® system features a probe which works like a metal detector. When it is placed near the skin’s surface, it can detect Endomag’s magnetic seed marker (Magseed®) and liquid tracer (Magtrace®), for accurate lesion localization and sentinel lymph node biopsy procedures. Endomag’s technologies have already helped 450,000+ women worldwide to access more precise, and minimally invasive breast cancer treatment. Contact Details Endomag Mary Nicholls +44 1223 652540 mnicholls@endomag.com

December 20, 2023 10:50 AM Eastern Standard Time

Image

Protecting Yourself from Respiratory Illnesses this Holiday Season

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/ZW6KvqOsf9M The holiday season is in full swing, and it's crucial to safeguard ourselves, our children, and our communities against respiratory illnesses like the outbreak we are seeing in China. Just when we thought it was safe to travel and gather for the holidays, pneumonia and RSV outbreaks here in the US and around the Globe are rising. With all the shopping, planning, cooking, and traveling, nobody wants to spend the holidays in bed sick or maybe even in the hospital fighting nasty viruses that continue to circle the globe. A nationwide media tour was conducted featuring President of the College of American Pathologists, Dr. Donald Karcher, sharing some tips on keeping you and your family safe when celebrating the holidays. Topics during the media tour that President of the College of American Pathologists, Dr. Donald Karcher, discussed included: · An understanding of exactly what is happening and how concerned we should be. · What can parents look for and do to mitigate the illness and the effect on the rest of the family, including elderly friends and relatives? · Why testing is still so important in corralling these illnesses. For more information, visit Newsroom.CAP.ORG Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

December 19, 2023 02:22 PM Eastern Standard Time

Video

Cardio Diagnostics’ Breakthrough Coronary Heart Disease Detection Test Published In The Journal Of The American Heart Association

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardio Diagnostics (NASDAQ: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine, has published a potentially revolutionary study in the Journal of the American Heart Association (JAHA). Conducted in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics, the publication details the development and validation of PrecisionCHD, a pioneering artificial intelligence-guided integrated genetic-epigenetic test for detecting coronary heart disease (CHD). Titled "The Validation of an Integrated Genetic-Epigenetic Test for the Assessment of Coronary Heart Disease," the article sheds light on Cardio Diagnostics’ progress in the field of cardiovascular medicine while showcasing PrecisionCHD’s ability to detect CHD with high sensitivity with a blood test and provide better testing access to underserved communities. Democratizing Access Traditional diagnostic methods for CHD, often inaccessible due to the need for specialized infrastructure, can be invasive and sometimes require exposure to ionizing radiation. Additionally, some of the tests are not sensitive to all forms of CHD and can be very costly, leaving millions of Americans without adequate and potentially lifesaving cardiac care. PrecisionCHD is the first integrated genetic-epigenetic test for the detection of CHD. With the introduction of PrecisionCHD, clinicians are armed with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test that uses artificial intelligence (AI), along with personalized genetic and epigenetic information, to detect the presence of CHD. Those who read the JAHA publication will learn about the development and validation of the PrecisionCHD test in three independent cohorts totaling 2,516 individuals. The study was collaboratively conducted by researchers from Cardio Diagnostics, Intermountain Healthcare and the University of Iowa Hospitals and Clinics. PrecisionCHD uses the input from six methylation sensitive digital PCR (MSdPCR) assessments to determine the presence or absence of CHD. The article details the mapping of each of these MSdPCR assays to distinct modifiable drivers of CHD, through which clinicians are able to gain personalized insights into each patient’s CHD presentation. It also notes that because methylation is dynamic, clinicians can consider focused re-testing to determine the effectiveness of CHD therapy. “What's truly revolutionary about this approach is its ability to provide a more comprehensive, personalized snapshot of a patient's CHD drivers, allowing for early intervention and tailored treatment plans,” said Robert Philibert MD Ph.D., lead author and Chief Medical Officer of Cardio Diagnostics. “This is personal for me; seeing patients who previously had limited options for early diagnosis now have access to this state-of-the-art technology is a milestone in cardiac care.” For rural communities where access to specialized medical facilities is limited, the implications of this research are particularly relevant. With only a simple blood draw needed to complete a test, PrecisionCHD offers patients in underserved areas access to state-of-the-art cardiac assessments. PrecisionCHD can be administered in primary care or telemedicine settings, significantly reducing the need for patients to travel to distant specialized clinics. This level of availability marks a step forward toward mitigating healthcare disparities, especially in rural areas with limited resources and infrastructure. “Our commitment is to democratize access to essential cardiac care, particularly in rural areas where advanced diagnostic tools are scarce and cardiovascular specialists are even more rare,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “PrecisionCHD's remote accessibility and deployment capability in non-specialized settings are pivotal in achieving this goal.” After recently finalizing an Innovation Technology contract with Vizient, Inc. – the nation’s largest provider-driven healthcare performance improvement company – Cardio Diagnostics will have access to a customer base that encompasses 60% of hospitals and 97% of academic medical centers in the United States. Member institutions have the ability to purchase the PrecisionCHD test through Vizient’s Innovative Technology Program. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

December 19, 2023 09:25 AM Eastern Standard Time

Redx Pharma CEO reports "good progress across the board"

Redx Pharma PLC

Redx Pharma PLC (AIM:REDX) CEO Lisa Anson speaks to Thomas Warner from Proactive after the clinical-stage biotechnology company released its final audited results for the year to 30 September. Anson discusses the company's performance in 2023 and outlined its plans for 2024. She highlights the successful launch of a Phase 2 program for lead asset Zelasudil, aimed at treating idiopathic pulmonary fibrosis, a challenging lung condition. Additionally, Anson touches upon another promising asset targeting the same mechanism, which is poised to enter clinical trials next year following extensive preclinical work. On the financial front, despite a challenging year, Redx Pharma successfully raised £14.1 million, ensuring funding through September 2024. This financial stability is crucial for achieving key milestones, which Anson believes will be pivotal for the company's growth. Looking ahead to 2024, Anson anticipates significant developments, including the release of Phase 2 data in idiopathic pulmonary fibrosis and resolving FDA regulatory issues in the first half of the year. Moreover, the company aims to initiate a Phase 1 study for its RXC008 (ROCK) asset, which would ne the sixth time Redx Pharma has brought a drug into clinical trials. In addition to these advances, Redx Pharma is also focusing on kidney fibrosis and oncology programs, with plans to progress these into clinical stages by 2026. Anson also emphasises the potential for new partnerships, particularly in advancing their oncology program for GI cancers, highlighting Redx Pharma's strategic approach to collaboration and development. This interview underlines Redx Pharma's significant strides in 2023 and sets a promising outlook for 2024, positioning the company as a key player in the pharmaceutical industry. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 19, 2023 07:25 AM Eastern Standard Time

Video

News Release

Voyageur Pharmaceuticals takes major step forward announcing international expansion

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to discuss the recent announcement regarding its international expansion and third-party manufacturing for barium sulfate products in the radiology market marks a significant development for the company. Voyageur has signed its first distribution deal with an international company. This is a crucial step in expanding its reach beyond Canada and tapping into global healthcare markets. Willis told Proactive the third-party manufacturing initiative is a precursor to the Francis Creek project, which is expected to significantly reduce production costs for barium sulfate. This cost reduction could enhance the company's competitiveness and profitability. The company is on track to conduct a bankable feasibility study for the Francis Creek project in early 2024. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

December 18, 2023 03:24 PM Eastern Standard Time

Video

1 ... 65 66 67 68 69 ... 302